Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines

The killed bivalent (O1 and O139) whole cell oral cholera vaccine (OCV) (Shanchol™) was first licensed in India in 2009 and World Health Organization pre-qualified in 2011. We assessed the safety and immunogenicity of this OCV in the Philippines. This was a phase IV, single-arm, descriptive, open-la...

Descripción completa

Detalles Bibliográficos
Autores principales: Capeding, Maria Rosario Z., Gonzales, Maria Liza Antoinette M., Dhingra, Mandeep Singh, D'Cor, Naveena Aloysia, Midde, Venkat Jayanth, Patnaik, Badri Narayan, Thollot, Yaël, Desauziers, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975480/
https://www.ncbi.nlm.nih.gov/pubmed/28910563
http://dx.doi.org/10.1080/21645515.2017.1342908

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975480/
https://www.ncbi.nlm.nih.gov/pubmed/28910563
http://dx.doi.org/10.1080/21645515.2017.1342908

Ejemplares similares